ライフサイエンスコーパス: very low density

1 factor for entry of HCVfrg subpopulations of very low density.

2 mental duplication, the mouse sequence has a very low density.

3 ion of 32 microbial families and genera with very-low-density and high-density subfractions, serum li

4 cause of increased assembly and secretion of very low density apolipoprotein B (apoB) and triglycerid

5 These materials have very low densities between 1.12 and 1.37 g cm(-3) and th

6 nzania than previously thought and that even very low-density chimpanzee populations can be infected

7 We show a very low-density, deep-seated upwelling that ascends ben

8 HCV- RNA was measured in the very-low-density fraction (VLDF, d < 1.025 g/mL) before

9 We also observed a minor population of very-low-density, >100-nm-diameter vesicular particles t

10 st in around 2.8% of the region, and live in very low densities in most of the areas.

11 , the S cones had an inverse topography with very low densities in the central retina and highest den

12 phospholipids, that were distributed in the very low density/intermediate density/low-density lipopr

13 Abnormalities in very low density lipoprotein (VLDL) assembly and secreti

14 ridemia was due largely to overproduction of very low density lipoprotein (VLDL) by the liver, a norm

15 Nascent very low density lipoprotein (VLDL) exits the endoplasmi

16 uptake of low density lipoprotein (LDL) and very low density lipoprotein (VLDL) particles by a singl

17 The transport of nascent very low density lipoprotein (VLDL) particles from the e

18 In contrast, the very low density lipoprotein (VLDL) pathway, which is re

19 incubations of apoA-I(-)(/)(-) apoE(-)(/)(-) very low density lipoprotein (VLDL) resulted in a 3-fold

20 intrahepatic triglyceride (IHTG) content and very low density lipoprotein (VLDL) triglyceride (TG) se

21 correlated to insulin resistance and plasma very low density lipoprotein (VLDL) triglycerides concen

22 sma apolipoprotein B yet increased levels of very low density lipoprotein (VLDL) triglycerides, sugge

23 correlate with metallocorrole affinities for very low density lipoprotein (VLDL), the main carrier of

24 cells do not express MTP and cannot secrete very low density lipoprotein (VLDL), yet they do not acc

25 ted apoE in accounting for the difference in very low density lipoprotein (VLDL)-induced adipocyte tr

26 easurements, hepatic metabolite analysis and very low density lipoprotein (VLDL)-TG secretion assays

27 oth human high density lipoprotein (HDL) and very low density lipoprotein (VLDL).

28 toma cells can mediate binding and uptake of very low density lipoprotein (VLDL).

29 ed for the hepatic assembly and secretion of very low density lipoprotein (VLDL).

30 h a Golgi-dependent mechanism while bound to very low density lipoprotein (vLDL).

31 In contrast, serum levels of very low density lipoprotein (VLDL)/low density lipoprot

32 tion and considerably decreases synthesis of very low density lipoprotein and its secretion in both l

33 of a subset of apolipoproteins implicated in very low density lipoprotein and triglyceride metabolism

34 a massive uptake of yolk precursors such as very low density lipoprotein and vitellogenin.

35 This tempers triglyceride availabiity for very low density lipoprotein assembly and allows homeost

36 sulfate and 2-O-sulfate groups did not block very low density lipoprotein binding and uptake in isola

37 1-tg mice had increased secretion of hepatic very low density lipoprotein but maintained plasma trigl

38 C), low density lipoprotein cholesterol, and very low density lipoprotein cholesterol (VLDL-C) assess

39 After 7 days, triglyceride (TG) levels and very low density lipoprotein cholesterol (VLDLc) levels

40 measurements revealed a 3.6-fold decrease of very low density lipoprotein cholesterol in serum and a

41 d fasting levels of plasma triglycerides and very low density lipoprotein cholesterol, and increased

42 rcumference, triglycerides, body mass index, very low density lipoprotein cholesterol, lipoprotein A,

43 first and rate-limiting step in chylomicron/very low density lipoprotein clearance at the luminal su

44 enesis of both apoB48 and apoB100-containing very low density lipoprotein in addition to a phospholip

45 at the assembled virions piggy-back onto the very low density lipoprotein particles for secretion.

46 s C virus (HCV) particles assemble along the very low density lipoprotein pathway and are released fr

47 Activation of very low density lipoprotein receptor (VLDLR) and apolip

48 Reelin signals via the lipoprotein receptors very low density lipoprotein receptor (VLDLR) and apolip

49 to apolipoprotein E receptor 2 (ApoER2) and very low density lipoprotein receptor (VLDLR) and is int

50 We discovered that miR-200c targets the very low density lipoprotein receptor (Vldlr) and its li

51 ApoE Receptor 2 (ApoER2) and the very low density lipoprotein receptor (VLDLR) are type I

52 The very low density lipoprotein receptor (VLDLR) is a membe

53 Previously, we have shown that very low density lipoprotein receptor (VLDLR) is virtual

54 induced choroidal neovascularization and the very low density lipoprotein receptor (Vldlr)-knockout m

55 scular entothelial growth factor [VEGF], and very low density lipoprotein receptor [VLDLR]) were test

56 Very low density lipoprotein receptor gene knock-out (Vl

57 ails of the lipoprotein receptors ApoER2 and very low density lipoprotein receptor through an amino-t

58 y, including the receptors ApoER2 and VLDLR (very low density lipoprotein receptor) and the adapter p

59 ells via apolipoprotein E receptor 2 and the very low density lipoprotein receptor, resulting in the

60 (d), approximately 30 nM) but not to soluble very low density lipoprotein receptor.

61 lls to acetylated low-density lipoprotein or very low density lipoprotein resulted in a time- and con

62 and increased secretion of triglyceride-rich very low density lipoprotein resulting in hypertriglycer

63 els were associated with both a reduction in very low density lipoprotein secretion and an increase i

64 ombined effect of inhibition of lipogenesis, very low density lipoprotein secretion and export of tri

65 Despite increased very low density lipoprotein secretion, apoB/BATless mic

66 cal increase in both hepatic lipogenesis and very low density lipoprotein secretion.

67 er of surface components of chylomicrons and very low density lipoprotein to high density lipoprotein

68 -IV, C-II, and C-III and increases serum and very low density lipoprotein triglyceride levels.

69 , via mitochondrial beta-oxidation and VLDL (very low density lipoprotein) secretion, causes excessiv

70 maller increases of most components of VLDL (very low density lipoprotein) subparticles.

71 olesterol into apoB-containing lipoproteins (very low density lipoprotein, intermediate density lipop

72 ewly formed lipid droplets, and yolk-derived very low density lipoprotein, shown to be efficiently en

73 , where rs964184 was associated with various very low density lipoprotein, triglyceride, and high-den

74 ich lipoproteins, including chylomicrons and very low density lipoprotein, which is the precursor to

75 protein distribution preference of apoE4 for very low density lipoprotein-sized particles.

76 Mttp produced a dramatic reduction in plasma very low density lipoprotein-TG and virtually eliminated

77 the increase in LPL activity, the uptake of very low density lipoprotein-TG is markedly reduced in a

78 ajor role in promoting uptake of circulating very low density lipoprotein-triglycerides (VLDL-TGs) in

79 without significant changes in plasma TG or very low density lipoprotein.

80 ngivalis levels was directly correlated with very low-density lipoprotein (P = 0.03) and triglyceride

81 oprotein (HDL(NMR)), 1.71 (1.38 to 2.12) for very low-density lipoprotein (VLDL(NMR)), and 2.25 (1.80

82 00014; African Americans P = 0.00417), large very low-density lipoprotein (VLDL) (Caucasians P = 0.00

83 the accumulation of free cholesterol in the very low-density lipoprotein (VLDL) and HDL region, and

84 apo) E between lipoprotein particles such as very low-density lipoprotein (VLDL) and high-density lip

85 idemia, the esterification of cholesterol of very low-density lipoprotein (VLDL) and high-density lip

86 usly found that EL is capable of hydrolyzing very low-density lipoprotein (VLDL) and LDL lipids ex vi

87 Very low-density lipoprotein (VLDL) and LDL plasma level

88 ) and the apolipoprotein B (apoB)-containing very low-density lipoprotein (VLDL) and low-density lipo

89 hydrolase (Ces3/TGH) participates in hepatic very low-density lipoprotein (VLDL) assembly and in adip

90 ty lipoprotein (LDL) cholesterol level, high very low-density lipoprotein (VLDL) cholesterol level, h

91 de (TG) levels resulting both from increased very low-density lipoprotein (VLDL) clearance and decrea

92 n decreased cholesterol levels and decreased very low-density lipoprotein (VLDL) fractions.

93 Increased production of very low-density lipoprotein (VLDL) is a critical featur

94 TGs, hepatosteatosis, and secrete lipid-poor very low-density lipoprotein (VLDL) lacking arachidonoyl

95 ue mass, and adipocyte cell size and reduced very low-density lipoprotein (VLDL) levels, as compared

96 monstrate that Sort1 alters plasma LDL-C and very low-density lipoprotein (VLDL) particle levels by m

97 ting impaired ER-to-Golgi trafficking of pre-very low-density lipoprotein (VLDL) particles.

98 NDGA inhibited very low-density lipoprotein (VLDL) secretion by affecti

99 ic pathways, such as triglyceride synthesis, very low-density lipoprotein (VLDL) secretion, and fatty

100 attenuation of hepatic steatosis, increased very low-density lipoprotein (VLDL) secretion, and impro

101 ignaling pathway, thereby regulating hepatic very low-density lipoprotein (VLDL) secretion, and subse

102 erized by a 3-fold higher liver secretion of very low-density lipoprotein (VLDL) that had apoC-III bu

103 by mitochondrial oxidation and secretion as very low-density lipoprotein (VLDL) triglycerides.

104 ein (HDL) subclasses and decreased levels of very low-density lipoprotein (VLDL), amino acids, and ci

105 mbination of size and concentrations of LDL, very low-density lipoprotein (VLDL), and high-density li

106 ined the lipidation and secretion of nascent very low-density lipoprotein (VLDL), finding that liver

107 h is needed for lipoprotein synthesis, e.g., very low-density lipoprotein (VLDL), the precursor of ci

108 experiments demonstrate that the LDLR has a very low-density lipoprotein (VLDL)-induced, FDNPVY-inde

109 nmol/L versus TT, 57.0+/-4.5 nmol/L; P=0.03) very low-density lipoprotein and chylomicron particle nu

110 ations, the variant was also associated with very low-density lipoprotein and high-density lipoprotei

111 ein B (apoB), the major protein component of very low-density lipoprotein and low-density lipoprotein

112 concentration of proatherogenic lipoproteins very low-density lipoprotein and low-density lipoprotein

113 in the maternal circulation, maternal plasma very low-density lipoprotein and other lipoproteins are

114 Very low-density lipoprotein and triglyceride concentrat

115 sm, and fatty acid compartmentalization; and very low-density lipoprotein assembly and secretion.

116 actor of 5 for the ratio of triglycerides to very low-density lipoprotein cholesterol (TG:VLDL-C); ho

117 l fibres reviewed reduced total cholesterol, very low-density lipoprotein cholesterol (VLDL-C) and LD

118 patient-specific ratios of triglycerides to very low-density lipoprotein cholesterol.

119 acylglycerols, apolipoproteins A-I and B, or very low-density lipoprotein cholesterol.

120 ssociation results for medium and very large very low-density lipoprotein composition are unlikely to

121 y lipoprotein levels and increased uptake of very low-density lipoprotein into Cxcr7-expressing white

122 uction in fasting plasma triacylglycerol and very low-density lipoprotein level coupled with slight i

123 Treatment with CCX771 reduced circulating very low-density lipoprotein levels but not low-density

124 0% less body weight gain and lower serum and very low-density lipoprotein levels of triglycerides but

125 ether inhibition of PCSK9 has any effects on very low-density lipoprotein or intermediate-density lip

126 infusion, followed by measurement of labeled very low-density lipoprotein palmitate via gas chromatog

127 The very low-density lipoprotein receptor (VLDLR) knockout (

128 le pathways including through the receptors, Very low-density lipoprotein receptor (Vldlr), Apolipopr

129 Mice deficient in another Reelin receptor, very low-density lipoprotein receptor (VLDLR), had norma

130 gnaling pathway that requires its receptors, very low-density lipoprotein receptor and apolipoprotein

131 ation and vascular leakage in the eyecups of very low-density lipoprotein receptor knockout mice, a m

132 Very low-density lipoprotein receptor mutant mice (Vldlr

133 uncation disrupts an interaction with VLDLR (very low-density lipoprotein receptor), while the APOER2

134 an interaction with the RELN receptor VLDLR (very low-density lipoprotein receptor); this was confirm

135 l blood vessels invading photoreceptors: the very low-density lipoprotein receptor-deficient (Vldlr(-

136 miR-34a inhibits very low-density lipoprotein secretion and promotes live

137 Blocking hepatic very low-density lipoprotein secretion through genetic o

138 genes involved in fatty acid beta-oxidation, very low-density lipoprotein secretion, and transcriptio

139 Choline metabolism is important for very low-density lipoprotein secretion, making this nutr

140 cal mechanisms and consequences of defective very low-density lipoprotein secretion.

141 and inadequate increases in IHTG export via very low-density lipoprotein secretion.

142 nover, which drives hepatic triglyceride and very low-density lipoprotein synthesis.

143 Uptake of DiI-labeled very low-density lipoprotein to adipose tissue was deter

144 men and women and measuring the synthesis of very low-density lipoprotein triglyceride (VLDL-TG) palm

145 ect has been shown to be caused by decreased very low-density lipoprotein triglyceride secretion rate

146 incorporation into palmitate of circulating very low-density lipoprotein triglyceride.

147 emic free fatty acids (FFA) into circulating very low-density lipoprotein triglycerides (VLDL-TGs) un

148 oxidation and export (as triglyceride within very low-density lipoprotein).

149 pairment in their catabolism of remnants and very low-density lipoprotein, an effect that was entirel

150 6449) has been associated with triglyceride, very low-density lipoprotein, and high-density lipoprote

151 nonexchangeable protein in chylomicrons and very low-density lipoprotein-derived lipoprotein particl

152 pact of anti-miR-33 therapy on the levels of very low-density lipoprotein-triglycerides (VLDL-TAG).

153 rosclerosis, considering they also had lower very low-density lipoprotein/low-density lipoprotein cho

154 No changes in plasma levels of very low-density lipoprotein/low-density lipoprotein, hi

155 in (HDL), low-density lipoprotein (LDL), and very-low density lipoprotein (VLDL), play a critical rol

156 Exported very-low density lipoprotein particles were isolated for

157 structural diversity in olive oil and human very-low density lipoprotein.

158 ptotic activity of HDL is inhibited by APOE4 very-low-density lipoprotein (APOE4-VLDL) in endothelial

159 protein subclasses were shifted toward lower very-low-density lipoprotein (P<0.001) and higher large

160 Cardiac utilisation of very-low-density lipoprotein (VLDL) and chylomicrons (CM

161 fects were mainly on serum triglycerides and very-low-density lipoprotein (VLDL) and its subclasses,

162 NT ASO exhibited a significant impairment in very-low-density lipoprotein (VLDL) binding that was ent

163 protein, high-density lipoprotein (HDL), and very-low-density lipoprotein (VLDL) cholesterol levels.

164 36 had significantly lower plasma TC, LDL-C, very-low-density lipoprotein (VLDL) cholesterol, and MDA

165 n of CETP were stronger on lower remnant and very-low-density lipoprotein (VLDL) cholesterol, but the

166 in plasma low-density lipoprotein (LDL) and very-low-density lipoprotein (VLDL) discriminated dengue

167 the notion that HCV coopts the secretion of very-low-density lipoprotein (VLDL) for its egress.

168 y reduced triglycerides and large and medium very-low-density lipoprotein (VLDL) particle concentrati

169 patitis C virus (HCV) uses components of the very-low-density lipoprotein (VLDL) pathway for assembly

170 hepatic triglycerides (TAG) associated with very-low-density lipoprotein (VLDL) play a major role in

171 FPIct) has been shown to be a ligand for the very-low-density lipoprotein (VLDL) receptor, we hypothe

172 ght but is associated with increased hepatic very-low-density lipoprotein (VLDL) secretion and elevat

173 glyceride content by threefold and decreased very-low-density lipoprotein (VLDL) secretion by 50%.

174 oaches, we demonstrate that vigilin controls very-low-density lipoprotein (VLDL) secretion through th

175 TG content, we measured hepatic lipogenesis, very-low-density lipoprotein (VLDL) secretion, and lipid

176 Genes for very-low-density lipoprotein (VLDL) synthesis (microsoma

177 rcise prevents fructose-induced increases in very-low-density lipoprotein (VLDL) triglycerides by dec

178 spectrometric analysis suggested that serum very-low-density lipoprotein (VLDL) was responsible for

179 -48-containing TRLs and apo B-100-containing very-low-density lipoprotein (VLDL), as well as on the e

180 inal) in lipoprotein fractions [chylomicron, very-low-density lipoprotein (VLDL), LDL, high-density l

181 weeks) for 8 weeks on the plasma kinetics of very-low-density lipoprotein (VLDL)-apolipoprotein B-100

182 ic and proteomic profiles implicated these 3 very-low-density lipoprotein (VLDL)-associated apolipopr

183 a marked suppression of the plasma levels of very-low-density lipoprotein (VLDL)-associated triglycer

184 e important for HCV cell-to-cell spread, but very-low-density lipoprotein (VLDL)-containing mouse ser

185 e observed strong positive associations with very-low-density lipoprotein (VLDL)-lipoproteins, VLDL-c

186 Very-low-density lipoprotein (VLDL)-triacylglycerols and

187 uh7 cells via pathways distinct from that of very-low-density lipoprotein (VLDL).

188 TG) and apolipoprotein C-III levels, and low very-low-density lipoprotein (VLDL)/high high-density li

189 Indeed, LpL mediated hydrolysis of very-low-density lipoprotein activated PPARalpha in card

190 ng aetiology via extensive associations with very-low-density lipoprotein and triglyceride metabolism

191 oward less high-density lipoprotein and more very-low-density lipoprotein and triglyceride particles

192 D-PDMP affected very-low-density lipoprotein catabolism by increasing th

193 2 to 63.1%), LDL cholesterol (1.3 to 32.9%), very-low-density lipoprotein cholesterol (27.9 to 60.0%)

194 at individual CpGs as a function of fasting very-low-density lipoprotein cholesterol and triglycerid

195 , hypoxia increased hepatic SCD-1 and plasma very-low-density lipoprotein cholesterol levels and indu

196 lic blood pressure, triglyceride levels, and very-low-density lipoprotein cholesterol levels, lesser

197 concentrations of triglyceride and low- and very-low-density lipoprotein cholesterol than controls,

198 mean concentrations of triglycerides (TGs), very-low-density lipoprotein cholesterol, and glucose we

199 triacylglycerols, apolipoprotein A-I and B, very-low-density lipoprotein cholesterol, and lipoprotei

200 Higher levels of apolipoprotein B, very-low-density lipoprotein cholesterol, triglycerides,

201 of macrophage LRP decreased uptake of (125)I-very-low-density lipoprotein compared with wild-type cel

202 significantly change serum triglycerides or very-low-density lipoprotein concentrations.

203 er high-density lipoprotein lipids and lower very-low-density lipoprotein lipids, glucose levels, bra

204 n, 95% confidence interval 3.48-6.78), other very-low-density lipoprotein measures, and branched-chai

205 MD -1.51%; 95% CI -3.75%, 0.74%; p = 0.189), very-low-density lipoprotein particle number (MD 3.79%;

206 0.70, 95% CI 0.65-0.76, p = 2x10(-)(1)(8)), very-low-density lipoprotein particle size (HR 0.69, 95%

207 rly in therapy, whereas TG concentration and very-low-density lipoprotein particle size decreased con

208 DL particles (0.77, 0.60-0.99, P=0.045), and very-low-density lipoprotein particles (0.78, 0.61-0.99,

209 mall LDL (0.78, 0.61-1.00, P=0.05) and small very-low-density lipoprotein particles (0.78, 0.62-0.99,

210 s, LDL particles, and select subfractions of very-low-density lipoprotein particles and LDL particles

211 zed with increasing levels of triglycerides, very-low-density lipoprotein particles, LDL-P, sdLDL-C,

212 e appearance in nonesterified fatty acid and very-low-density lipoprotein pools was negatively associ

213 ing, quantitative polymerase chain reaction, very-low-density lipoprotein production, adenovirus over

214 revealed a point mutation, c.2239C>T, in the very-low-density lipoprotein receptor (Vldlr) gene.

215 Very-low-density lipoprotein receptor (VLDLR) in knockou

216 Very-low-density lipoprotein receptor (VLDLR) is a multi

217 The very-low-density lipoprotein receptor (VLDLR) negatively

218 Very-low-density lipoprotein receptor (Vldlr), which is

219 retinopathy and another angiogenic model of very-low-density lipoprotein receptor (Vldlr)-deficient

220 by binding to the two lipoprotein receptors, very-low-density lipoprotein receptor and apolipoprotein

221 ER2 (apolipoprotein E receptor 2) and VLDLR (very-low-density lipoprotein receptor).

222 e gene expression for lipoprotein lipase and very-low-density lipoprotein receptor.

223 rs, apolipoprotein E receptor 2 (Apoer2) and very-low-density lipoprotein receptor.

224 eceptors for Reelin, including integrins and very-low-density lipoprotein receptor/apolipoprotein E2

225 Very-low-density lipoprotein secretion, which is absent

226 atic free fatty acid oxidation, or decreased very-low-density lipoprotein secretion.

227 sity lipoprotein cholesterol subclasses, and very-low-density lipoprotein subclasses did not improve

228 events was also observed for several LDL and very-low-density lipoprotein subfractions but not for io

229 CVD/all-cause death, as were several LDL and very-low-density lipoprotein subfractions, albeit with a

230 mol/min for LowLF; P = .41) or production of very-low-density lipoprotein triacylglycerol from FFAs (

231 sociations were observed for extremely large very-low-density lipoprotein triglycerides (odds ratio [

232 ze and concentrations of LDLNMR and VLDLNMR (very-low-density lipoprotein) particles were negatively

233 Serum triglyceride, very-low-density lipoprotein, and apolipoprotein B level

234 ty lipoprotein, low-density lipoprotein, and very-low-density lipoprotein, can be easily separated an

235 poprotein, intermediate-density lipoprotein, very-low-density lipoprotein, lipoprotein (a), or chylom

236 They exist in three major classes: very-low-density lipoprotein, low-density lipoprotein, a

237 ot related with the immune system, including very-low-density lipoprotein, vitellogenin, estrogen rec

238 were used to assess insulin sensitivity and very-low-density lipoprotein-triglyceride (VLDL-TG) secr

239 rate decreased by 27% +/- 7% (P < .01); and very-low-density lipoprotein-triglyceride secretion rate

240 plasma total, high-density lipoprotein, and very-low-density lipoprotein/low-density lipoprotein cho

241 rocessed human milk and O-glycoproteins from very-low-density-lipoprotein (vLDL) particles.

242 Here we show that maternal very-low-density-lipoprotein (VLDL) receptor deletion in

243 protein (HDL) yields 4-6% of the LDL signal, very-low-density-lipoprotein (VLDL) yields 1-3%, and hum

244 , particularly in the cholesterol content of very-low-density lipoproteinparticles.

245 n the hepatic secretion of apoB-100-carrying very low density lipoproteins (VLDL) and a decrease in t

246 The major protein component in secreted very low density lipoproteins (VLDL) is apoB, and it is

247 accelerated hepatic fatty acid oxidation and very low density lipoproteins (VLDL) secretion.

248 transient depression of hepatic secretion of very low density lipoproteins (VLDL).

249 riglyceride into plasma through secretion of very low density lipoproteins (VLDL).

250 iating FFA uptake or triglyceride release as very low density lipoproteins (VLDL).

251 iglyceride (TAG)-rich lipoproteins including very low density lipoproteins (VLDLs) and chylomicrons,

252 sma from apoA-I(-/-) mice or purified low or very low density lipoproteins but readily opacified HDL.

253 arily because of its role in the assembly of very low density lipoproteins by the liver and chylomicr

254 the secretion of cholesteryl ester-enriched very low density lipoproteins by the liver.

255 ally derived chylomicrons and injected human very low density lipoproteins to the same extent as obse

256 ch was due to a decrease in the secretion of very low density lipoproteins.

257 creased hepatic secretion of TG into nascent very low density lipoproteins.

258 t dictates the synthesis of chylomicrons and very low density lipoproteins.

259 (HDL) to the proatherogenic low-density and very low-density lipoproteins (LDL and VLDL).

260 Procollagens, pre-chylomicrons, and pre-very low-density lipoproteins (pre-VLDLs) are too big to

261 DL are further isolated by precipitating the very low-density lipoproteins (VLDL) and low-density lip

262 (CE), and triglyceride (TG) from plasma and very low-density lipoproteins (VLDL) was used to measure

263 Raman signature of single optically trapped very low-density lipoproteins (VLDL), a subclass of TGRL

264 re to triglyceride-rich lipoproteins such as very low-density lipoproteins (VLDL).

265 Excessive secretion of triglyceride-rich very low-density lipoproteins (VLDL-TG) contributes to d

266 epatitis C virus (HCV) and triglyceride-rich very low-density lipoproteins (VLDLs) both are secreted

267 ip between CD36 expression and serum HDL and very low-density lipoproteins (VLDLs) levels was also ex

268 lesterol and triglycerides, respectively, in very low-density lipoproteins (VLDLs).

269 metabolism, especially in the biogenesis of very low-density lipoproteins and chylomicrons via the t

270 lipoproteins, low-density lipoproteins, and very low-density lipoproteins contained elevated apoA-I

271 Rs of very low-density lipoproteins-apoB and very low-density lipoproteins triglycerides or on postpr

272 cholesterol to triglycerides ratio (1.52) in very low-density lipoproteins with elevated levels of sm

273 plasmic reticulum export of chylomicrons and very low-density lipoproteins, but not collagen XII.

274 ) dictates the formation of chylomicrons and very low-density lipoproteins, two major lipoprotein pre

275 by the inability to produce chylomicrons or very low-density lipoproteins, with the absence of apoli

276 Alirocumab had no effects on FCRs or PRs of very low-density lipoproteins-apoB and very low-density

277 poC-III and apoC-IV levels were decreased in very low-density lipoproteins.

278 in B (apoB)-containing lipoproteins (hepatic very-low density lipoproteins), which leads to hyperlipi

279 Very-low-density lipoproteins (VLDL) are metabolic precu

280 Very-low-density lipoproteins (VLDL) is a hallmark of me

281 in a manner that parallels the formation of very-low-density lipoproteins (VLDL).

282 fasting triacylglycerol in chylomicrons and very-low-density lipoproteins (VLDLs) (P = 0.004), reduc

283 actor ANOVA) in plasma (P = 0.023) and large very-low-density lipoproteins (VLDLs) (P = 0.016) and po

284 ty liver as a result of reduced secretion of very-low-density lipoproteins (VLDLs).

285 at transfers alpha-tocopherol (vitamin E) to very-low-density lipoproteins (VLDLs).

286 was observed in systolic BP (7.1 mm Hg) and very-low-density lipoproteins (VLDLs; 5.16 mg/dL) in gro

287 ipoproteins, including low-density (LDL) and very-low-density lipoproteins and chylomicrons.

288 ity lipoprotein cholesterol, a surrogate for very-low-density lipoproteins and low-density lipoprotei

289 studies with [(3)H]cholesteryl ether-labeled very-low-density lipoproteins demonstrated that the HL/E

290 triglyceride secretion, lower lipidation of very-low-density lipoproteins, and increased lipid dropl

291 B level, concentration and particle size of very-low-density lipoproteins, concentration of low-dens

292 (surrogates for low-density lipoproteins and very-low-density lipoproteins, respectively), the RR was

293 suggesting that it arises from lipolysis of very-low-density lipoproteins.

294 of HCV E2 protein with human and bovine LPs (very low density, low density, and high density) enhance

295 mate the size of the components, we derive a very low density of 0.8(- 0.1)+0.2 g cm(-3).

296 ined by the expression on their surface of a very low density of CD44 (CD44(v.low) cells), can inhibi

297 The superior material quality with a very low density of defects and very high compositional

298 Despite the very low density of the complexes at the cell surface, E

299 adic Creutzfeldt-Jakob disease (CJD) bind to very low-density (VLDL) and low-density (LDL) lipoprotei

300 osae), a slow growing climax tree, occurs at very low densities, whereas J. copaia (Bignoniaceae) is